Skip to main content

Table 1 Baseline demographic and disease characteristics

From: Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

Demographic characteristic OASIS Adalimumab Pvaluea
  Number Baseline assessment Number Baseline assessment  
Age, years 168 43.6 ± 12.7 307 41.8 ± 11.5 0.101
Male, percentage 169 69.2 307 76.5 0.102
Weight, kg 157 72.7 ± 12.8 307 80.0 ± 16.3 < 0.001
Height, cm 161 171.0 ± 9.3 306 172.9 ± 9.5 0.037
Concomitant medications, percentage      
   NSAIDs 169 77.5 307 88.3  
   DMARDs 169 9.5 307 21.8  
   Systemic glucocorticoids 169 1.8 307 9.8  
Disease characteristic      
   Disease duration, years 163 11.3 ± 8.7 307 11.2 ± 9.3 0.946
   BASDAI, 0-10 166 3.4 ± 2.1 307 6.2 ± 1.7 < 0.001
   BASFI, 0-10 158 3.1 ± 2.4 307 5.3 ± 2.1 < 0.001
   Total back pain, 0-10 166 3.5 ± 2.4 307 6.7 ± 1.9 < 0.001
   Inflammation, 0-10b 167 3.4 ± 2.6 307 6.7 ± 2.0 < 0.001
   Patient's Global Assessment of disease activity, 0-10 165 3.7 ± 2.7 306 6.4 ± 2.0 < 0.001
   C-reactive protein, mg/dLc 160 1.5 ± 1.9 302 1.9 ± 2.5 0.036
   mSASSS, 0-72 169 15.8 ± 17.6 307 19.8 ± 19.3 0.028
  1. Values are mean ± standard deviation unless otherwise noted. aP values calculated using one-way analysis of variance or the Fisher exact test. No statistical comparison of concomitant medications was completed. bMean of questions 5 and 6 of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). cUsing the ultrasensitive assay (normal range, 0.007 to 0.494 mg/dL). BASFI, Bath Ankylosing Spondylitis Functional Index; DMARD, disease-modifying antirheumatic drug; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NSAID, nonsteroidal anti-inflammatory drug; OASIS, Outcome in Ankylosing Spondylitis International Study.